EuroAPI EuroAPI

X
[{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Files Patent Application to Extend Exclusivity of Rabeximod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cyxone AB"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Cyxone AB"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Will Leverage IND and Use FDA Pre-Review for Covid-19 Phase 2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Cyxone AB"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma BAGS MHRA Nod for Covd-19 Trial in Record Time","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vicore Pharma"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Doses First COVID-19 Patient in the ATTRACT Study in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vicore Pharma"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Reports Positive Top Line Data from the Attract Clinical Study in Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vicore Pharma"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results Show that C21 Can Become an Important Complement to COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vicore Pharma"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data From Phase II study ATTRACT in Patients with COVID-19 Published Online: Vicore Pharma Holding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Vicore Pharma"},{"orgOrder":0,"company":"ILYA Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clearance of IND for First-in-class ILP100-topical Immunotherapy Treatment of Surgical Wounds in Patients With Prediabetes, Diabetes and Obesity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"ILYA Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            ILP100-Topical (emilimogene sigulactibac) is a first-in-class immunotherapy designed to treat surgical wounds in patients with prediabetes, diabetes and obesity.

            Lead Product(s): Emilimogene Sigulactibac

            Therapeutic Area: Infections and Infectious Diseases Product Name: ILP100

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Rabeximod is is an orally administered immunomodulator being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections.

            Lead Product(s): Rabeximod

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 24, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The results show restoration of lung function in COVID-19 on top of corticosteroids and remdesivir with the company's oral drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.

            Lead Product(s): C21

            Therapeutic Area: Infections and Infectious Diseases Product Name: VP01

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery.

            Lead Product(s): Rabeximod

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The data show restoration of lung function in COVID-19 with the company’s oral lead candidate drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.

            Lead Product(s): VP01

            Therapeutic Area: Infections and Infectious Diseases Product Name: C21

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The ATTRACT study investigated the efficacy of oral C21 compared with placebo in COVID-19 patients with signs of an acute respiratory infection but not requiring mechanical ventilation. Oral C21 treatment demonstrates significant clinical improvement on top of corticosteroids.

            Lead Product(s): VP01

            Therapeutic Area: Infections and Infectious Diseases Product Name: C21

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.

            Lead Product(s): Rabeximod

            Therapeutic Area: Infections and Infectious Diseases Product Name: Rob 803

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The primary objective with the study, named ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial), is to investigate efficacy of VP01 (C21) on COVID-19 infection not requiring mechanical ventilation.

            Lead Product(s): VP01

            Therapeutic Area: Infections and Infectious Diseases Product Name: C21

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Vicore Pharma got approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to start a Phase II clinical trial assessing a potential COVID-19 therapy in record time.

            Lead Product(s): VP01

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 01, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY